NeuroSense Therapeutics Ltd. Cash and Cash Equivalents
NeuroSense Therapeutics Ltd. (NRSN) had Cash and Cash Equivalents of $166.00 thousand as of 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-03-31
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $166.00K.
- 2025-06-30: Cash and Cash Equivalents, at Carrying Value $666.00K.
- 2024-12-31: Cash and Cash Equivalents, at Carrying Value $3.38M.
- 2024-06-30: Cash and Cash Equivalents, at Carrying Value $1.21M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2025-12-31 | $166.00K 20-F · filed 2026-03-31 |
| 2025-06-30 | $666.00K 6-K · filed 2025-08-01 |
| 2024-12-31 | $3.38M 20-F · filed 2026-03-31 |
| 2024-06-30 | $1.21M 6-K · filed 2024-09-30 |
| 2023-12-31 | $2.64M 20-F · filed 2025-04-07 |
| 2022-12-31 | $3.54M 6-K · filed 2024-06-17 |